LXRX NASDAQ
Lexicon Pharmaceuticals, Inc.
1W: +1.1%
1M: -18.8%
3M: -21.6%
YTD: +51.7%
1Y: +59.6%
3Y: +5.2%
5Y: -46.8%
$1.82
+0.00 (+0.00%)
Weekly Expected Move ±8.3%
$2
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$808.4M
52W Range1.1-2.68
Volume2,316,584
Avg Volume3,242,257
Beta1.03
Dividend—
Analyst Ratings
Company Info
CEOMichael S. Exton
Employees81
SectorHealthcare
IndustryBiotechnology
IPO Date2000-04-07
Websitelexpharma.com
2445 Technology Forest Boulevard
The Woodlands, TX 77381
US
The Woodlands, TX 77381
US
281 863 3000
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
Latest News
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Up – Here’s What Happened
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
Lexicon a new overweight at Cantor on optimism for Inpefa in cardiomyopathy
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Recommendation of “Hold” from Brokerages
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Swain Judith L | M-Exempt | 89,312 | — | 2026-06-03 |
| Swain Judith L | M-Exempt | 89,312 | — | 2026-06-03 |
| Sullivan Diane E. | M-Exempt | 89,312 | — | 2026-06-03 |
| Sullivan Diane E. | M-Exempt | 89,312 | — | 2026-06-03 |
| SOBECKI CHRISTOPHER | M-Exempt | 89,312 | — | 2026-06-03 |